Pharmaceutical regulatory affairs consultancy specialising in preclinical data quality, vaccine development strategy, and AI-assisted regulatory modelling.
PharmaLex is a specialist pharmaceutical regulatory affairs and compliance consultancy that supports drug and vaccine developers through the complex process of getting products approved and to market. In H2020 projects, they bring deep expertise in regulatory strategy, quality standards, and the translation of research findings into frameworks that satisfy health authority requirements. Their participation in preclinical data quality and vaccine innovation consortia suggests their primary value-add is bridging scientific research with the regulatory and quality processes that determine whether a product can actually be used in clinical practice. They are not a laboratory — they are the organisation that tells researchers how to document, structure, and present their work so regulators will accept it.
Both EQIPD and Inno4Vac address regulatory-facing challenges — data quality standards and accelerated vaccine development — where regulatory expertise is a core deliverable, not just background knowledge.
EQIPD (European Quality In Preclinical Data) directly targets the standardisation of preclinical research quality, a field where regulatory consultancies play a central role in defining acceptance criteria.
Inno4Vac involves controlled human infection models, in vitro models, AI-assisted modelling, and manufacturing — topics where regulatory guidance on novel trial designs and production standards is critical.
Inno4Vac keywords include artificial intelligence and modelling, indicating growing engagement with computational and data-driven tools as they enter the regulatory approval pipeline.
Their first H2020 project (EQIPD, 2017–2021) placed them squarely in the field of preclinical data quality — a foundational, standards-driven area concerned with making research more reproducible and regulator-ready. Their second project (Inno4Vac, 2021–2027) represents a clear shift toward active vaccine innovation, with keywords spanning controlled human infection models, AI, in vitro systems, and mucosal biology — all at the frontier of next-generation vaccine science. The trajectory suggests PharmaLex Belgium is deliberately moving from quality assurance frameworks into earlier-stage, more technically ambitious innovation projects where regulatory expertise must engage directly with novel science.
They are moving upstream in the drug development pipeline — from ensuring existing data meets quality standards toward shaping how novel vaccine technologies (AI models, in vitro systems, human challenge trials) are designed to meet future regulatory expectations.
PharmaLex Belgium participates exclusively as a consortium partner and has never led an H2020 project, which is consistent with their role as a specialist service provider brought in by academic or industry consortium builders who need regulatory expertise on the team. With 68 unique partners across just 2 projects, they operate within very large, multi-stakeholder consortia — both EQIPD and Inno4Vac are IMI or RIA projects with broad European membership. This means they are comfortable in complex governance structures but are unlikely to initiate or administratively lead a project.
Despite only two projects, PharmaLex Belgium has built a surprisingly broad network of 68 unique consortium partners spanning 14 countries, reflecting the large IMI2 and RIA consortia they have joined. Their network is genuinely European in character, with no indication of geographic concentration toward Belgium or the Benelux region.
PharmaLex is one of the few large specialist regulatory consultancies — rather than academic institutions or pharma manufacturers — participating directly in H2020 health research consortia, which gives them a distinctive vantage point across both science and regulatory practice. Their value to a consortium is not generating new data but ensuring that what the consortium produces will survive contact with EMA, FDA, or national health authority scrutiny. For a consortium building in vaccine, biologics, or preclinical research that lacks in-house regulatory expertise, PharmaLex Belgium fills a gap that universities and research institutes typically cannot.
